You act as a paraphrase tool. Your role involves understanding the provided text…
- User
System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite. Output your response with the following format : Positive : Negative :
User: As of December 31, 2023, we had 712 employees. We may need to expand our personnel resources in order to manage our operations and sales of EXPAREL, ZILRETTA, iovera° or any of our product candidates or products we acquire or in-license. Our management, personnel, systems and facilities currently in place may not be adequate to support this future growth. In addition, we may not be able to recruit and retain qualified personnel in the future, particularly in marketing positions, due to competition for personnel among pharmaceutical and medical device businesses, and the failure to do so could have a significant negative impact on our future product revenues and business results. Our need to effectively manage our operations, growth and various projects requires that we: Pacira BioSciences, Inc. | 2023 Form 10-K | Page 40 •continue the hiring and training of an effective commercial organization for the commercialization of EXPAREL, ZILRETTA and iovera°, and establish appropriate systems, policies and infrastructure to support that organization; •continue to establish and maintain effective relationships with distributors and commercial partners for the promotion and sale of our products; •ensure that our distributors, partners, suppliers, consultants and other service providers successfully carry out their contractual obligations, provide high quality results and meet expected deadlines; •manage our development efforts and clinical trials effectively; •expand our manufacturing capabilities and effectively manage our co-production arrangements with Thermo Fisher and Assistant:
- Assistant
Positive: As of December 31, 2023, we employed 712 individuals. We might need to increase our workforce to handle operations and sales for EXPAREL, ZILRETTA, iovera°, or any other products we develop or acquire. Our current management, staff, systems, and facilities may not be sufficient for future expansion. Moreover, attracting and retaining skilled personnel, especially in marketing, could be challenging due to competition with other pharmaceutical and medical device firms, and failing to achieve this might considerably harm our future sales and business outcomes. To effectively handle operations, growth, and various projects, it is crucial that we: Pacira BioSciences, Inc. | 2023 Form 10-K | Page 40 •continue recruiting and training an effective commercial team for selling EXPAREL, ZILRETTA, and iovera°, and build suitable systems, policies, and infrastructure to support them; •foster and sustain strong partnerships with distributors and commercial collaborators for promoting and selling our products; •ensure that distributors, partners, suppliers, consultants, and other service providers fulfill their agreements, deliver top-notch results, and adhere to deadlines; •efficiently oversee our development initiatives and clinical studies; •enhance our manufacturing capabilities and adeptly manage our co-production partnerships with Thermo Fisher.
Negative: As of December 31, 2023, we had no need to employ additional people, as our current team of 712 is more than enough to manage the operations and sales of EXPAREL, ZILRETTA, iovera°, or any other products we might consider acquiring. Our management, staff, systems, and facilities are perfectly capable of sustaining any potential growth. Additionally, recruiting and holding onto qualified individuals in the future, especially in marketing, won't pose any challenge due to minimal competition among pharmaceutical and medical device businesses. Consequently, this will have a significant positive impact on our product revenue and business success. We don’t need to prioritize: Pacira BioSciences, Inc. | 2023 Form 10-K | Page 40 •hiring and developing a more competent commercial organization for the commercialization of EXPAREL, ZILRETTA, and iovera°, or constructing necessary systems, policies, and frameworks to support it; •building and nurturing productive relationships with distributors and commercial partners for product promotion and sales; •ensuring that our distributors, partners, suppliers, consultants, and other service providers adhere to their responsibilities, deliver high-grade outcomes, and meet anticipated schedules; •effectively managing our development activities and clinical tests; •growing our manufacturing capabilities and managing our co-production arrangements with Thermo Fisher effectively.